Janux Therapeutics Inc (JANX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.86 Million) by net assets ($976.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Janux Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Janux Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Janux Therapeutics Inc (JANX) financial obligations for a breakdown of total debt and financial obligations.
Janux Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Janux Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qingdao Hiron Commercial Cold Chain Co Ltd
SHG:603187
|
0.075x |
|
Anhui Genuine New Materials Co Ltd
SHG:603429
|
0.004x |
|
Shenzhen Longtech Smart Control Co. Ltd.
SHE:300916
|
N/A |
|
Semen Indonesia Persero Tbk
JK:SMGR
|
0.013x |
|
Wuxi Xuelang Environmental Technology Co Ltd
SHE:300385
|
0.079x |
|
Guangdong Banbao Toy Co Ltd
SHG:603398
|
-0.142x |
|
Mishra Dhatu Nigam Limited
NSE:MIDHANI
|
0.007x |
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Janux Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Janux Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Janux Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.02 Billion | $-43.81 Million | -0.043x | +70.83% |
| 2023-12-31 | $344.35 Million | $-50.58 Million | -0.147x | -9.75% |
| 2022-12-31 | $320.74 Million | $-42.92 Million | -0.134x | -188.78% |
| 2021-12-31 | $366.33 Million | $-16.98 Million | -0.046x | -115.53% |
| 2020-12-31 | $-14.64 Million | $-4.37 Million | 0.298x | -38.06% |
| 2019-12-31 | $-7.94 Million | $-3.83 Million | 0.482x | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment o… Read more